Cargando…

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs

BACKGROUND: The patterns and determinants of saxagliptin use among patients with type 2 diabetes mellitus (T2DM) are unknown in real-world settings. We compared the characteristics of T2DM patients who were new initiators of saxagliptin to those who were new initiators of non-dipeptidyl peptidase-4...

Descripción completa

Detalles Bibliográficos
Autores principales: Saine, M Elle, Carbonari, Dena M, Newcomb, Craig W, Nezamzadeh, Melissa S, Haynes, Kevin, Roy, Jason A, Cardillo, Serena, Hennessy, Sean, Holick, Crystal N, Esposito, Daina B, Gallagher, Arlene M, Bhullar, Harshvinder, Strom, Brian L, Re, Vincent Lo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404079/
https://www.ncbi.nlm.nih.gov/pubmed/25889498
http://dx.doi.org/10.1186/s40360-015-0007-z
_version_ 1782367440578019328
author Saine, M Elle
Carbonari, Dena M
Newcomb, Craig W
Nezamzadeh, Melissa S
Haynes, Kevin
Roy, Jason A
Cardillo, Serena
Hennessy, Sean
Holick, Crystal N
Esposito, Daina B
Gallagher, Arlene M
Bhullar, Harshvinder
Strom, Brian L
Re, Vincent Lo
author_facet Saine, M Elle
Carbonari, Dena M
Newcomb, Craig W
Nezamzadeh, Melissa S
Haynes, Kevin
Roy, Jason A
Cardillo, Serena
Hennessy, Sean
Holick, Crystal N
Esposito, Daina B
Gallagher, Arlene M
Bhullar, Harshvinder
Strom, Brian L
Re, Vincent Lo
author_sort Saine, M Elle
collection PubMed
description BACKGROUND: The patterns and determinants of saxagliptin use among patients with type 2 diabetes mellitus (T2DM) are unknown in real-world settings. We compared the characteristics of T2DM patients who were new initiators of saxagliptin to those who were new initiators of non-dipeptidyl peptidase-4 (DPP-4) inhibitor oral anti-diabetic drugs (OADs) and identified factors associated with saxagliptin use. METHODS: We conducted a cross-sectional study within the Clinical Practice Research Datalink (CPRD), The Health Improvement Network (THIN), US Medicare, and the HealthCore Integrated Research Database (HIRD(SM)) across the first 36 months of saxagliptin availability (29 months for US Medicare). Patients were included if they were: 1) ≥18 years old, 2) newly prescribed saxagliptin or a non-DPP-4 inhibitor OAD, and 3) enrolled in their respective database for 180 days. For each saxagliptin initiator, we randomly selected up to ten non-DPP-4 inhibitor OAD initiators matched on age, sex, and geographic region. Conditional logistic regression was used to identify determinants of saxagliptin use. RESULTS: We identified 64,079 saxagliptin initiators (CPRD: 1,962; THIN: 2,084; US Medicare: 51,976; HIRD(SM): 8,057) and 610,660 non-DPP-4 inhibitor OAD initiators (CPRD: 19,484; THIN: 19,936; US Medicare: 493,432; HIRD(SM): 77,808). Across all four data sources, prior OAD use, hypertension, and hyperlipidemia were associated with saxagliptin use. Saxagliptin initiation was also associated with hemoglobin A1c results >8% within the UK data sources, and a greater number of hemoglobin A1c measurements in the US data sources. CONCLUSIONS: In these UK and US data sources, initiation of saxagliptin was associated with prior poor glycemic control, prior OAD use, and diagnoses of hypertension and hyperlipidemia. TRIAL REGISTRATION: ClinicalTrials.gov identifiers NCT01086280, NCT01086293, NCT01086319, NCT01086306, and NCT01377935
format Online
Article
Text
id pubmed-4404079
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44040792015-04-21 Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs Saine, M Elle Carbonari, Dena M Newcomb, Craig W Nezamzadeh, Melissa S Haynes, Kevin Roy, Jason A Cardillo, Serena Hennessy, Sean Holick, Crystal N Esposito, Daina B Gallagher, Arlene M Bhullar, Harshvinder Strom, Brian L Re, Vincent Lo BMC Pharmacol Toxicol Research Article BACKGROUND: The patterns and determinants of saxagliptin use among patients with type 2 diabetes mellitus (T2DM) are unknown in real-world settings. We compared the characteristics of T2DM patients who were new initiators of saxagliptin to those who were new initiators of non-dipeptidyl peptidase-4 (DPP-4) inhibitor oral anti-diabetic drugs (OADs) and identified factors associated with saxagliptin use. METHODS: We conducted a cross-sectional study within the Clinical Practice Research Datalink (CPRD), The Health Improvement Network (THIN), US Medicare, and the HealthCore Integrated Research Database (HIRD(SM)) across the first 36 months of saxagliptin availability (29 months for US Medicare). Patients were included if they were: 1) ≥18 years old, 2) newly prescribed saxagliptin or a non-DPP-4 inhibitor OAD, and 3) enrolled in their respective database for 180 days. For each saxagliptin initiator, we randomly selected up to ten non-DPP-4 inhibitor OAD initiators matched on age, sex, and geographic region. Conditional logistic regression was used to identify determinants of saxagliptin use. RESULTS: We identified 64,079 saxagliptin initiators (CPRD: 1,962; THIN: 2,084; US Medicare: 51,976; HIRD(SM): 8,057) and 610,660 non-DPP-4 inhibitor OAD initiators (CPRD: 19,484; THIN: 19,936; US Medicare: 493,432; HIRD(SM): 77,808). Across all four data sources, prior OAD use, hypertension, and hyperlipidemia were associated with saxagliptin use. Saxagliptin initiation was also associated with hemoglobin A1c results >8% within the UK data sources, and a greater number of hemoglobin A1c measurements in the US data sources. CONCLUSIONS: In these UK and US data sources, initiation of saxagliptin was associated with prior poor glycemic control, prior OAD use, and diagnoses of hypertension and hyperlipidemia. TRIAL REGISTRATION: ClinicalTrials.gov identifiers NCT01086280, NCT01086293, NCT01086319, NCT01086306, and NCT01377935 BioMed Central 2015-04-02 /pmc/articles/PMC4404079/ /pubmed/25889498 http://dx.doi.org/10.1186/s40360-015-0007-z Text en © Saine et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Saine, M Elle
Carbonari, Dena M
Newcomb, Craig W
Nezamzadeh, Melissa S
Haynes, Kevin
Roy, Jason A
Cardillo, Serena
Hennessy, Sean
Holick, Crystal N
Esposito, Daina B
Gallagher, Arlene M
Bhullar, Harshvinder
Strom, Brian L
Re, Vincent Lo
Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs
title Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs
title_full Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs
title_fullStr Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs
title_full_unstemmed Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs
title_short Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs
title_sort determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404079/
https://www.ncbi.nlm.nih.gov/pubmed/25889498
http://dx.doi.org/10.1186/s40360-015-0007-z
work_keys_str_mv AT sainemelle determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs
AT carbonaridenam determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs
AT newcombcraigw determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs
AT nezamzadehmelissas determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs
AT hayneskevin determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs
AT royjasona determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs
AT cardilloserena determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs
AT hennessysean determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs
AT holickcrystaln determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs
AT espositodainab determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs
AT gallagherarlenem determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs
AT bhullarharshvinder determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs
AT strombrianl determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs
AT revincentlo determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs